Skip to main content

Qiagen to Provide Intradigm with siRNA in Drug Discovery Collaboration

NEW YORK, July 8 - Qiagen and Intradigm will collaborate in siRNA drug discovery research & development projects, the companies said today.

 

Under the agreement, Qiagen will manufacture the siRNA (short interfering RNA), which it will provide to Intradigm for research in oncology, arthritis, and SARS.

 

For the SARS coronavirus project, Intradigm will design at least 48 sets of siRNA oligos for delivery through the airways, as a potential treatment for the pulmonary infection caused by the virus. The company said it will conduct this project with collaborators at the National Institute of Allergy and Infectious Diseases, as well as ones in Hong Kong and Guangzhou,China

 

The companies did not disclose the financial terms of the agreement.

 

Qiagen, of Venlo, the Netherlands, manufactures siRNA for gene silencing using its TOM-Amidite chemistry. The company is one of four companies licensed to supply siRNA under a group of patent applications held by MIT, the Whitehead Institute, the Max Planck Institute, and the University of Massachusetts Medical School.

 

Intradigm, of Rockville, Md., has developed methods of delivering siRNA in animals, and has conducted studies to validate particular siRNA agents for cancer and viral infection.

 

SiRNA consists of a short double-stranded sequence of RNA that is delivered into a cell, which triggers the destruction of the mRNA from a target gene.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.